Abstract
The $A_{2B}$ adenosine receptor ($A_{2B}R$) is a critical G protein-coupled receptor (GPCR) involved in regulating inflammation, heart rhythm, and tumor immunity. Unlike other adenosine receptors, $A_{2B}R$ exhibits a low affinity for its endogenous ligand, adenosine, requiring micromolar concentrations for activation. This study presents the first high-resolution cryo-EM structures of the active $A_{2B}R-G_s$ complex bound to both adenosine and the synthetic agonist BAY 60-6583. Our findings reveal a unique "gatekeeper" residue, $V250^{6.51}$, which defines the receptor's selectivity and provides a structural basis for the development of $A_{2B}R$-targeted therapeutics.
Introduction
Adenosine signaling is a ubiquitous physiological process mediated by four receptor subtypes: $A_1R, A_{2A}R, A_{2B}R,$ and $A_3R$. While $A_1R$ and $A_{2A}R$ respond to nanomolar levels of adenosine, $A_{2B}R$ is only activated under conditions of high adenosine concentration, such as hypoxia or inflammation. This low sensitivity makes $A_{2B}R$ a unique therapeutic target for acute lung injury, myocardial ischemia, and cancer immunotherapy. However, the lack of structural data has hindered the design of selective drugs. This research provides the first structural blueprint of the active $A_{2B}R$ state.
Methods
Researchers utilized cryogenic electron microscopy (cryo-EM) to determine the structures of $A_{2B}R$ coupled to a modified $G_s$ protein. Two complexes were resolved: $A_{2B}R$ bound to adenosine (ADO) at 3.2 Å and $A_{2B}R$ bound to the synthetic agonist BAY 60-6583 at 2.9 Å. To validate the structural findings, the team performed three independent 500 ns Molecular Dynamics (MD) simulations to assess ligand stability and NanoBiT functional assays to measure the impact of specific mutations on receptor signaling.
Key Insights and Results
The V6.51 Gatekeeper
The most significant structural discovery is the role of residue $V250^{6.51}$. In the more sensitive $A_1R$ and $A_{2A}R$ subtypes, this position is occupied by a bulky Leucine. In $A_{2B}R$, the smaller Valine creates a larger orthosteric cavity. This allows the synthetic drug BAY 60-6583 to bind deeper within the pocket, explaining its high selectivity for $A_{2B}R$ over other subtypes. Mutagenesis experiments confirmed this; replacing Valine with Leucine in $A_{2B}R$ significantly reduced the potency of BAY 60-6583.
Adenosine Binding and Stability
MD simulations revealed that while adenosine binds to $A_{2B}R$ in a similar orientation to other adenosine receptors, it is significantly less stable in the $A_{2B}R$ pocket. The ligand exhibits higher root mean squared deviation (RMSD) values during simulation, suggesting that the "wobble" within the larger cavity contributes to the receptor's low natural affinity.
Conserved Activation Mechanism
Despite the unique binding pocket, the overall activation mechanism of $A_{2B}R$ aligns with the classic GPCR model. Activation involves a characteristic outward displacement of transmembrane helix 6 (TM6) and an upward shift of TM3 to accommodate the G protein coupling. The synthetic agonist BAY 60-6583 mimics the interactions of adenosine's pyrimidine group through its pyridine ring, maintaining essential $\pi$-stacking with $F173^{45.52}$.
Discussion and Future Directions
This study provides a high-resolution framework for understanding $A_{2B}R$ pharmacology. While the current structures clarify $G_s$ coupling, $A_{2B}R$ is known to also signal through $G_q$ proteins, a mechanism that remains to be structurally characterized. Additionally, the role of water networks in the binding pocket—well-documented in $A_{2A}R$—requires further investigation at higher resolutions. These structures now serve as a template for virtual screening to identify novel, potent, and selective $A_{2B}R$ modulators for clinical use.
Summary updated